Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the importance of real…
Browsing: Breast Cancer
Breast Cancer Treatment Resources
Breast cancer treatment options are evolving rapidly, and OncologyTube’s Breast Cancer Treatment category is your go-to source for the latest insights. Explore expert-led videos, clinical trial updates, and research from leading oncologists. Whether you’re seeking information on chemotherapy, immunotherapy, or surgical options, our curated content helps patients and professionals stay informed. Browse our collection to discover breakthroughs like the EMBER-3 Trial for advanced care.
Why Trust OncologyTube?
Our content features trusted experts like Dr. Saranya Chumsri, a triple-negative breast cancer specialist, ensuring credible and actionable insights. We collaborate with top institutions to bring you reliable information tailored to your needs.
Latest Breast Cancer Research
Stay updated with cutting-edge studies and trials, such as ASCO 2025 highlights on targeted therapies. Our videos break down complex topics into clear, actionable information for patients and caregivers. Learn about innovative approaches like PARP inhibitors and their impact on HER2-positive cases.
Patient and Professional Resources
OncologyTube offers tools for both patients and healthcare providers. Patients can find support resources, while professionals can access updates on clinical guidelines from sources like ASCO and ESMO. Explore our video library for interviews with experts discussing real-world treatment challenges and solutions.
Explore More
Check out related content like Dr. Chumsri’s video on triple-negative breast cancer or dive into our Immunotherapy Category for complementary insights. For trusted guidelines, visit the National Cancer Institute or ASCO.
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes…
Enrique Soto, MD @EnriqueSoto8 of Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán @incmnszmx discusses the real world outcomes…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses the impact of multigenomic assays in premenopausal patients and those with…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast…
Michael Gnant, MD of University of Vienna @MedUni_Vienna discusses using multigenomic assays in premenopausal patients and those with node-positive breast…
Rebecca Nagy of Guardant Health Inc. discusses women with metastatic hormone receptor-positive (HR+) breast cancer having experienced improved clinical outcomes…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine explains how important it is to tailor treatment for triple-negative breast cancer patients.…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine answers how come interferon gamma is acting differently? _____________ Immunotherapies have revolutionized care…
Rumela Chakrabarti, PhD of Penn Medicine @PennMedicine discusses tailoring revolutionary treatment for triple-negative breast cancer. _____________ Immunotherapies have revolutionized care…
Earn CME: https://www.naccme.com/program/19-cpc-101-1 This webcast features a presentation by Dr. Nicole M. Kuderer that examines pharmacological profiles of novel and…
Nick McAndrew, MD MSCE Clinical Instructor Division of Hematology / Oncology UCLA David Geffen School of Medicine discusses updates in…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses the effects of cardiac toxicities in the phase 3 CLEOPATRA study…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer answers common questions in the phase 3 CLEOPATRA study in HER2 metastatic…
Sandra Swain, MD @SandraSwainMD of Georgetown Lombardi @LombardiCancer discusses findings in the phase 3 CLEOPATRA study in HER2 metastatic breast…
While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation…
Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich answers commonly asked questions in pharmacogenomics and endocrine therapy in breast…
– Application Supported by Results of Pivotal HER2CLIMB Trial -Â – First Investigational Therapy in a Pivotal Trial to Include…
Daniel Hayes, MD @hoosierdfh of University of Michigan @UMich discusses endocrine therapy in breast cancer.
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer explains getting results down in oral paclitaxel: a Phase III clinical…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer answers frequently asked questions on paclitaxel shown to be superior to…
Gerardo Antonio Umanzor, MD of Liga Contra el Cáncer on paclitaxel shown to be superior to IV paclitaxel on confirmed…
First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic…
GRACE is very excited to bring you more of our program on supportive care in cancer treatment.Arjun Gupta, MD, one…
Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the…
Ramon Parsons, MD, PhD @Ramon_Parsons of @IcahnMountSinai discusses a novel agent that degrades a protein called EZH2 that drives the…
Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study. _____________ MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering…
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of…
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is…
Luca Malorni, MD of Prato Hospital discusses a marker in operable breast cancer at SABCS 19. __________ The study is…
Jennifer Crozier, MD of @BaptistHealthSA discusses the FLEX real world data in early stage breast cancer.
William Audeh, MD of @Agendia discusses new data presented at SABCS demonstrating how genomic profiling benefits early stage breast cancer.
– TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium® – New…
MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results for Kisqali plus fulvestrant, reducing…
First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in…
Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer answers nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy: how can…
Oluwadamilola “Lola” Fayanju, MD @DrLolaFayanju of @DukeCancer explains the nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after…
V.K. Gadi, MD of @SeattleCCA answers commonly asked questions of the AVIATOR study and shares how it will affect future…
V.K. Gadi, MD of @SeattleCCA discusses the AVIATOR study for HER2-positive metastatic breast cancer. __________ Read here:Â https://www.seattlecca.org/clinical-trials/breast-cancer-nct03414658
Address to Japan Society of Clinical Oncology focuseson opportunities to expand benefits to more patients Accomplished surgeon-scientist joined Roswell Park…
Peter O’Donnell, MD of @UChicagoMed provides results from biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab…
Peter O’Donnell, MD of @UChicagoMed explains biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab in phase…
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer provides information on trends in breast cancer death rates.
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer explains breast cancer trends in the U.S.
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs and how this…
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs for patients with…
Zhibo Ma, PhD of @salkinstitute explains mapping normal breast development to try and better understand cancer. __________ Breast cancer is…
Zhibo Ma, PhD of @salkinstitute explains how this affects treatment and clinicians today. __________ Breast cancer is one of the…
Zhibo Ma, PhD of @salkinstitute answers common questions asked by colleagues regarding measuring chromatin accessibility changes in breast cancer. ________…
Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different…
Xiao-Ou Shu, MD of @VUMChealth explains how oncologists should treat male breast cancer patients and how it will affect clinicians.…
Research from the UAB’s O’Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had…
Xiao-Ou Shu, MD of @VUMChealth explains that in a recent study, men have a higher mortality rate than women due…
Once breast cancer spreads to bone, treatment becomes nearly impossible. Breast cancer cells can lie dormant in the bone, often…
Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5…
With Breast Cancer Awareness Month Approaching, Cedars-Sinai Experts Discuss New Treatment Options for Early-Stage, Low-Risk Breast Cancer Patients LOS ANGELES…
Gregory Senofsky, MD of UCLA Health explains the standard conversion rate form lumpectomy to mastectomy. ______ FINDINGS Breast cancer surgeons…
Gregory Senofsky, MD of UCLA Health addresses how reducing the need for second surgery after lumpectomy will affect clinicians today…
Gregory Senofsky, MD of UCLA Health answers a question often asked by colleagues. ______ FINDINGS Breast cancer surgeons performing lumpectomies…
Gregory Senofsky, MD of UCLA Health explains the intraoperative teamwork that greatly reduces the need for second surgery after lumpectomy.…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in…
GRACEcast-133_Breast_Elderly Breast Cancer Part 4 Advanced and Functional Assessment of Patients
GRACEcast-132_Breast_Elderly Breast Cancer Part 3 Surgery and the Value of Adjuvant Therapy
GRACEcast-130_Breast_Elderly Breast Cancer Part 2 Prevention Screening and Goals of Treatment
GRACEcast-128_Breast_Older Women with Breast Cancer Part 1 Defining Population Trends by Age.mp4
What To Discuss With Your Healthcare Team – a Diagnosis of Triple Negative Breast Cancer – Litton
What makes a triple negative breast cancer negative Reis Filho
Review of Recent Progress in Immunotherapy in Triple Negative Breast Cancer Schmid
Current Standard of Care in Triple Negative Breast Cancer – Yardley
Combination therapy IO Chemo in Triple Negative Breast Cancer Schmid
BRCA Mutations What does it Mean When Choosing My Treatment Litton
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists explains the results from the SOPHIA trial, a phase…
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares…
Neelima Denduluri MD, Associate Chair, US Oncology Research, Virginia Cancer Specialists explains the MONALESSA-7 trial outcomes in premenopausal metastatic breast…
Neelima Denduluri MD @ndenduluri1 Of US Oncology Research Discusses Updates On Patient Care From ASCO: New Ways To Educate Patients…
Scott Koenig, of Macrogenics, discusses what it will take to gain regulatory approval. About MacroGenics, Inc. MacroGenics is a clinical-stage…
Scott Koenig, of Macrogenics, discusses achieving a better outcome for patients. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company…
Scott Koenig discusses the data on the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company…
Scott Koenig discusses the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company focused on discovering…
Lee Schwartzberg MD @oncstatdoc Of West Cancer Center Discusses Intravenous NEPA Study: Combination Therapy To Prevent CINV In Patients Receiving…
Hannah Linden MD Of The University of Washington School of Medicine Discusses What We Specialize In: Multidisciplinary Approach, One Stop…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Palbociclib & Alpelisib: Improved Survival Benefit In Younger…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Hired Expert In Molecular Imaging: Huge Opportunity To…
Hannah Linden MD Of The University of Washington School of Medicine Discusses Estrogen Receptor Imaging: Specialty Diagnostic Test That Can…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
GRACE – Global Resource for Advancing Cancer Education Published on Mar 26, 2019 GRACE is excited to bring to you…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-01 With a focus on integrating recent advances into improved care pathways, this on-demand…
Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, Sensoring Process, QOL. At ESMO Oncology Conference – Munich,…
Hope Rugo, M.D., University Of California San Francisco discusses EMBRACA Trial, FDA Approval Of Talazoparib. At ESMO Oncology Conference -…
Hope Rugo, M.D., University Of California San Francisco discusses Data On Neoadjuvant Talazoparib. At ESMO Oncology Conference – Munich, Germany…
Managing side effects can be an overwhelming experience for oncology patients, they may be unsure of the severity of their…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Improving Survival in Stage 4 Breast Cancer | S0226 Showed That…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Fasching, MD, from University…
In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Avoiding Chemotherapy in Subset of Patients | TAILORx Uses Scoring Method…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about Cyclin-Dependent Kinases to Endocrine Therapy | Adding CDK-46 inhibitors to Frontline…
Rita Sanghvi Mehta, MD, UC Irvine Health, explains High-Dose Fulvestrant Vs. Loading Dose | Loading Dose Prevents Early Progressions at…
Rita Sanghvi Mehta, MD, UC Irvine Health, explains how Patients were Given Anastrozole + Fulvestrant | Some Patients Over-Represented in…
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about SWOG S0226 – for Metastatic Breast Cancer | Addition of Fulvestrant…
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Schmid, MD, PhD, FRCP,…
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses the promising efficacy data of sacituzumab govitecan, an anti-Trop-2/SN-38…
The treatment landscape of metastatic breast cancer (mBC) is advancing rapidly. Here, Aditya Bardia, MD, MPH, of Massachusetts General Hospital,…
Douglas W. Blayney, MD, explains the significant improvement in PFS in the fulvestrant + ribociclib arm of the MONALEESA-3 study…
Neelima Denduluri, MD, shares the results of the PERSEPHONE trial in early HER2+ breast cancer mean that 6 months of…
Julie Gralow, MD, talks about how to differentiate CDK4/6 inhibitors and whether they can be used interchangeably.
Douglas W. Blayney, MD, Professor of Medicine, Associate Division Chief of Medical Oncology, Stanford Healthcare, on the significant improvement in…
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting,…
Trastuzumab has revolutionized the treatment of HER2+ breast cancer; however, the benefit of a longer duration of this therapy is…
Neelima Denduluri, MD, talks about how to differentiate CDK4/6 inhibitors and whether they be used interchangeably
Douglas W. Blayney, MD, explains differentiating CDK4/6 Inhibitors and if they can be used interchangeably.
Neelima Denduluri, MD, shares her thoughts on the practice-changing results of the TAILORx study presented at the 2018 Annual Meeting.
Neelima Denduluri, MD, shares her thoughts on the implications of the TAILORx study at the 2018 Annual Meeting.
Sara M. Tolaney, MD, MPH, talks about whether the results of the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene…
Sara M. Tolaney, MD, MPH, talks about the TAILORx study in HR+, HER2-, node-negative, intermediate 21-gene recurrence score patients, means…
Sara M. Tolaney, MD, MPH, the fulvestrant + ribociclib arm of the MONALEESA-3 study
Sara M. Tolaney, MD, MPH, talks about whether CDK4/6 inhibitors can be used interchangeably at Annual Meeting 2018.
Sara M. Tolaney, MD, MPH shares the MONARCH 2 study in pre and peri-menopausal ER+, HER2- breast cancer patients
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares Use PARP-Inhibitors Early in Therapy for Metastatic Breast…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco explains Talazoparib is Effective in Neoadjuvant Setting | Combine…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trastuzumab-DKST has Regulatory Approval in US |…
Hope S. Rugo, MD, FAnnual Meeting, University of California, San Francisco shares the Trial for PARP-Inhibitor for Germ-Line in BRCA1…
Hannah Linden, MD, University of Washington shares Publish New Abstract Data Next Year | Complete Accrual of Estrogen Receptor Imaging…
Hannah Linden, MD, University of Washington shares The Point of Estrogen Receptor Imaging? | If Receptor Functions & Need Endocrine…
Hannah Linden, MD, University of Washington shares ER Imaging Not Ready for Commercial Use | Working Hard With Tracer Manufacturers…
Hannah Linden, MD, University of Washington shares Estrogen Receptor Imaging | Lobular Tumors Detectable by FES PET
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Therapies for Metastatic Breast Cancer | Clinical Trial Development is Key to…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Triple Negative Breast Cancer Immunotherapies | Pemborlizumab works in NeoAdjuvant Setting at…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Vaccine Immunotherapy with Cytoxan & Interferon | Eventually add Ipilimumab or Pembrolizumab…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Metastatic Breast Cancer Does Well with Bria-IMT Side-Effect Profile Not as Severe…
Saveri Bhattacharya, DO, Thomas Jefferson University, talks about Phase 1 & 2 Trial of Bria-IMT | Immunotherapy with Cytoxan &…
Jennifer K. Litton, MD, explains The Number of Agents Has Exploded Impactful Studies Happen with Federal Funding at Annual Meeting…
Jennifer K. Litton, MD, MD Anderson Cancer Center, talks about TAILORx Trial is Confirmatory Group of Patients Avoiding Chemo-Therapy at…
Jennifer K. Litton, MD, MD Anderson Cancer Center, talks about Warranting Larger Ongoing Confirmatory Study Possibility of Avoiding Chemo-Therapy in…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Biopsies Pre- & Post-PARP inhibitors Combination Studies for Response Beyond BRCA…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Warrants Larger Ongoing Confirmatory Study Possibility of Avoiding Chemo-Therapy in BRCA…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Feasibility Study with 2 Months of Talazoparib Tumor Volume Decrease of…
Jennifer K. Litton, MD, MD Anderson Cancer Center, shares Talazoparib – Active in Metastatic Breast Cancer Pathologic Complete Response Rate…
Chuck Wiseman, MD, BriaCell Therapeutics, talks about Rollover Protocol Approval Bria-IMT in combination with a checkpoint inhibitor at Annual Meeting…
Chuck Wiseman, MD BriaCell Therapeutics, discusses Cell Preparation Bria-IMT Confirms that similar vaccine therapies can regress advances at Annual Meeting…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN & SEC23B Novel Predisposition Genes Prediction tools for…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Altered For Rare Blood Disorder Type II…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains SEC23B is Very Rarely Studied in Cancer Enters the…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains KLLN is Right Next to PTEN Gene Might play…
Charis Eng, MD, PhD, Genomic Medicine Institute – Cleveland Clinic, explains 3D Modeling of PTEN Tumor Suppressor at AACR 2018.